Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Winkelmann

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Neurology|March 30, 2022
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T CellsPhilipp Karschnia, Kai Rejeski, Michael Winkelmann, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 2, 2024
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentationNabeel Mansour, Kathrin Heinrich, Danmei Zhang, et al.
European Radiology|January 25, 2025
Effect of artificial intelligence-aided differentiation of adenomatous and non-adenomatous colorectal polyps at CT colonography on radiologists' therapy managementSergio Grosu, Matthias P Fabritius, Michael Winkelmann, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 7, 2024
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentationNabeel Mansour, Kathrin Heinrich, Danmei Zhang, et al.
Clinical Nuclear Medicine|October 2, 2024
Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18 F-SiTATESophie C Kunte, Lena M Unterrainer, Wolfgang G Kunz, et al.
Annals of Hematology|October 20, 2023
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Neurology|March 30, 2022
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T CellsPhilipp Karschnia, Kai Rejeski, Michael Winkelmann, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 2, 2024
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentationNabeel Mansour, Kathrin Heinrich, Danmei Zhang, et al.
European Radiology|January 25, 2025
Effect of artificial intelligence-aided differentiation of adenomatous and non-adenomatous colorectal polyps at CT colonography on radiologists' therapy managementSergio Grosu, Matthias P Fabritius, Michael Winkelmann, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 7, 2024
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentationNabeel Mansour, Kathrin Heinrich, Danmei Zhang, et al.
Clinical Nuclear Medicine|October 2, 2024
Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18 F-SiTATESophie C Kunte, Lena M Unterrainer, Wolfgang G Kunz, et al.
Annals of Hematology|October 20, 2023
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Pageof 5